Literature DB >> 7961854

Domains of phosphatase inhibitor-2 involved in the control of the ATP-Mg-dependent protein phosphatase.

I K Park1, A A DePaoli-Roach.   

Abstract

Inhibitor-2 (I-2) inhibits the free catalytic subunit of type 1 phosphatase (CS1) and controls the cyclic inactivation/activation of CS1 in the ATP-Mg-dependent protein phosphatase complex. We report here the effect of mutations on these two properties of I-2. Substitution of Thr-72 with Ala, Asp, or Glu generated complexes with CS1 that could not be activated. Mutation of Ser-86 did not affect activation by glycogen synthase kinase-3 (GSK-3) alone but impaired synergistic activation by casein kinase II and GSK-3. Mutations in the region between Thr-72 and Ser-86 did not alter the inhibitory potency of I-2 but prevented complete inactivation of CS1. A mutant without the 35 NH2-terminal residues exhibited an IC50 for CS1 200-fold higher than that of wild-type I-2. However, it formed an inactive phosphatase complex with CS1, which was activated by GSK-3. A mutant with the 59 COOH-terminal residues deleted retained full inhibitory activity and formed an inactive complex that could not be activated by GSK-3. We conclude that the NH2-terminal region of I-2 is involved in inhibition, that the sequence between Thr-72 and Ser-86 is necessary for the conversion of CS1 from an active to an inactive conformation, and that the COOH terminus is required for activation by GSK-3. Thus, different functional domains of I-2 may interact with distinct regions of CS1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961854

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Successful overexpression of wild-type inhibitor-2 of PP1 in cardiovascular cells.

Authors:  Thorsten Krause; Stefanie Grote-Wessels; Felix Balzer; Peter Boknik; Ulrich Gergs; Uwe Kirchhefer; Igor B Buchwalow; Frank U Müller; Wilhelm Schmitz; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-24       Impact factor: 3.000

2.  Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection.

Authors:  Kun Don Yi; James W Simpkins
Journal:  Endocrinology       Date:  2008-06-19       Impact factor: 4.736

3.  The Toxoplasma gondii inhibitor-2 regulates protein phosphatase 1 activity through multiple motifs.

Authors:  Quentin Deveuve; Kevin Lesage; Thomas Mouveaux; Mathieu Gissot
Journal:  Parasitol Res       Date:  2017-06-30       Impact factor: 2.289

4.  Protein phosphatase 1 regulation by inhibitors and targeting subunits.

Authors:  T Watanabe; H B Huang; A Horiuchi; E F da Cruze Silva; L Hsieh-Wilson; P B Allen; S Shenolikar; P Greengard; A C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  The C-terminus of NIPP1 (nuclear inhibitor of protein phosphatase-1) contains a novel binding site for protein phosphatase-1 that is controlled by tyrosine phosphorylation and RNA binding.

Authors:  M Beullens; V Vulsteke; A Van Eynde; I Jagiello; W Stalmans; M Bollen
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

Review 6.  Protein phosphatase-1 and insulin action.

Authors:  L Ragolia; N Begum
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

7.  Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins.

Authors:  Y G Kwon; H B Huang; F Desdouits; J A Girault; P Greengard; A C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

8.  The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels.

Authors:  Taj D King; Johanna C Gandy; Gautam N Bijur
Journal:  Exp Cell Res       Date:  2006-08-17       Impact factor: 3.905

9.  Detailed structural characterization of unbound protein phosphatase 1 inhibitors.

Authors:  Barbara Dancheck; Angus C Nairn; Wolfgang Peti
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

10.  Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity.

Authors:  Anil Kumar; Thurl E Harris; Susanna R Keller; Kin M Choi; Mark A Magnuson; John C Lawrence
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.